183 related articles for article (PubMed ID: 34559291)
21. Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.
Hashmi AA; Hussain ZF; Irfan M; Edhi MM; Kanwal S; Faridi N; Khan A
BMC Res Notes; 2018 Mar; 11(1):207. PubMed ID: 29587848
[TBL] [Abstract][Full Text] [Related]
22. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
[TBL] [Abstract][Full Text] [Related]
23. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract][Full Text] [Related]
24. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
25. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.
Corr BR; Finlay-Schultz J; Rosen RB; Qamar L; Post MD; Behbakht K; Spillman MA; Sartorius CA
Int J Gynecol Cancer; 2015 Nov; 25(9):1565-73. PubMed ID: 26495758
[TBL] [Abstract][Full Text] [Related]
26. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
Jumppanen M; Gruvberger-Saal S; Kauraniemi P; Tanner M; Bendahl PO; Lundin M; Krogh M; Kataja P; Borg A; Fernö M; Isola J
Breast Cancer Res; 2007; 9(1):R16. PubMed ID: 17263897
[TBL] [Abstract][Full Text] [Related]
27. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
Fichtenbaum EJ; Marsh WL; Zynger DL
Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
[TBL] [Abstract][Full Text] [Related]
28. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors.
Skinnider BF; Folpe AL; Hennigar RA; Lim SD; Cohen C; Tamboli P; Young A; de Peralta-Venturina M; Amin MB
Am J Surg Pathol; 2005 Jun; 29(6):747-54. PubMed ID: 15897741
[TBL] [Abstract][Full Text] [Related]
29. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
30. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
31. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
32. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung.
Savci-Heijink CD; Kosari F; Aubry MC; Caron BL; Sun Z; Yang P; Vasmatzis G
Am J Pathol; 2009 May; 174(5):1629-37. PubMed ID: 19342368
[TBL] [Abstract][Full Text] [Related]
33. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas.
Camilo R; Capelozzi VL; Siqueira SA; Del Carlo Bernardi F
Hum Pathol; 2006 May; 37(5):542-6. PubMed ID: 16647951
[TBL] [Abstract][Full Text] [Related]
34. Expressions of Thyroid Transcription Factor-1, Napsin A, p40, p63, CK5/6 and Desmocollin-3 in Non-Small Cell Lung Cancer, as Revealed by Imprint Cytology Using a Malinol-Based Cell-Transfer Technique.
Kawai T; Tominaga S; Hiroi S; Kameda K; Ogata S; Nakashima H; Ozeki Y; Nakanishi K
Acta Cytol; 2015; 59(6):457-64. PubMed ID: 26696549
[TBL] [Abstract][Full Text] [Related]
35. [Expression of cytokeratins 5/6 and cytokeratin 17 in invasive breast carcinoma].
Ivković-Kapicl T; Panjković M; Nikolić I; Djilas-Ivanović D; Knezević-Usaj S
Vojnosanit Pregl; 2012 Dec; 69(12):1031-8. PubMed ID: 23424955
[TBL] [Abstract][Full Text] [Related]
36. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
37. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens.
Khayyata S; Yun S; Pasha T; Jian B; McGrath C; Yu G; Gupta P; Baloch Z
Diagn Cytopathol; 2009 Mar; 37(3):178-83. PubMed ID: 19170169
[TBL] [Abstract][Full Text] [Related]
38. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
39. Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice.
Mohammad T; Garratt J; Torlakovic E; Gilks B; Churg A
Am J Surg Pathol; 2012 Oct; 36(10):1503-8. PubMed ID: 22982894
[TBL] [Abstract][Full Text] [Related]
40. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H
J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
